多发性骨髓瘤是一种多发性骨髓瘤
Marc S Raab1, Klaus Podar, Iris Breitkreutz
1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Lancet (London, England)
|June 23, 2009
概括
多发性骨髓瘤涉及恶性血细胞和骨髓微环境. 针对两者的新疗法改善了多发性骨髓瘤和其他癌症患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
背景情况:
- 多发性髓瘤是一种恶性血细胞的癌症.
- 骨髓微环境在髓瘤的发展和进展中起着至关重要的作用.
研究的目的:
- 审查骨髓微环境在多发性髓瘤发病过程中的作用.
- 要突出针对骨髓瘤细胞及其微观环境的新型治疗剂的影响.
主要方法:
- 对多发性骨髓瘤及其治疗现有文献的综述.
- 对thalidomide, bortezomib和lenalidomide等药物的作用机制的分析.
主要成果:
- 针对骨髓微环境与髓瘤细胞一起,提高了治疗效率.
- 像thalidomide, bortezomib和lenalidomide这样的药物已经显示出显著的益处.
- 这些药物改善了整体反应,反应持续时间,无进展生存率和整体生存率.
结论:
- 骨髓微环境是多发性骨髓瘤的关键治疗点.
- 将这些新型药物纳入一线治疗方案为患者提供了更好的结果.
- 这种治疗方法对其他血液性恶性瘤和固体瘤也具有前景.
相关概念视频
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:27Disorders of Leukocytes
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...